Comparison of the effects of combined ramosetron with midazolam and palonosetron with midazolam for postoperative nausea and vomiting prophylaxis in patients undergoing laparoscopic cholecystectomy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008767

Enrollment

Registered

2023-09-07

Start date

2023-01-04

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In the midazolam + ramosetron group, 50 µg/kg midazolam is intravenously administered 10 minutes before surgery, and 0.3mg ramosetron is intravenously administered immediately before the end of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA physical status 1-2 patients aged 20-65 years undergoing laparoscopic cholecystectomy, patients who agreed to participate in this clinical study

Exclusion criteria

Exclusion criteria: Smokers, patients with a history of opioid abuse, hypersensitivity to ramosetron or palonosetron, patients who received antiemetics within 24 hours before surgery, pregnancy, breastfeeding, patients who refused to participate in this clinical study

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative nausea and vomiting	—

Secondary

Measure	Time frame
Severity of postoperative nausea;Additional administration of antiemetic drugs	—

Countries

Korea, Republic of

Contacts

Public ContactJung A Lim

Daegu Catholic University Medical Center

definitebud@naver.com+82-53-650-3265

Outcome results